glp-1 gastrointestinal obstruction attorney in louisiana semaglutide Ozempic Lawsuit [May 2026 Update] Louisiana Ozempic Lawyer | Injury
Description
FDA labeling sets GLP-1 weight-management eligibility at BMI 30+ or BMI 27+ with a comorbidity
![glp-1 gastrointestinal obstruction attorney in louisiana semaglutide Ozempic Lawsuit [May 2026 Update] Louisiana Ozempic Lawyer | Injury](https://www.shreveportlawyer.com/wp-content/uploads/2023/10/Shreveport-Ozempic-Lawyer.jpg)
The findings appeared
![glp-1 gastrointestinal obstruction attorney in louisiana semaglutide Ozempic Lawsuit [May 2026 Update] Louisiana Ozempic Lawyer | Injury](https://www.atlantalegalcare.com/wp-content/uploads/2026/02/GLP-1-lawyer-top-photo.png)
On September 19, 2025, the FDA issued Import Alert 66-80, which authorizes field staff to detain without physical examination shipments of GLP-1 active On September 19, 2025, the FDA issued Import Alert 66-80, which authorizes field staff to detain without physical examination shipments of GLP-1 active pharmaceutical ingredients (APIs) from manufacturers not included on its newly established "Green List.
Prescription product
Discover BIKAYALUE GLP-1 Patches with 14-in-1 plant formula
![glp-1 gastrointestinal obstruction attorney in louisiana semaglutide Ozempic Lawsuit [May 2026 Update] Louisiana Ozempic Lawyer | Injury](https://shunnarah.com/wp-content/uploads/2025/09/glp-1-weight-loss-drugs-1024x768.jpg)